APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monogenic Disease Testing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Monogenic Disease Testing Market Analysis and Forecast 2026-2032

17 January 2026194 pages

Choose your research edition.

Industry ResearchMonogenic Disease Testing Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Monogenic Disease Testing Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Monogenic Disease Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monogenic Disease Testing Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Monogenic Disease Testing Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Monogenic Disease Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Monogenic Disease Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Monogenic Disease Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Monogenic Disease Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Monogenic Disease Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Monogenic Disease Testing include Celera Support Services, Abbott, ELITech Group, Auto Genomics, PerkinElmer and Bio-Rad Laboratories, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Monogenic Disease Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Monogenic Disease Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Monogenic Disease Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Monogenic Disease Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Monogenic Disease Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Monogenic Disease Testing revenue, projected growth trends, production technology, application and end-user industry.

Monogenic Disease Testing Segment by Company

Celera Support Services

Abbott

ELITech Group

Auto Genomics

PerkinElmer

Bio-Rad Laboratories

Monogenic Disease Testing Segment by Type

Carrier Testing

Diagnostic Testing

New-Born Screening

Predictive and Pre-Symptomatic Testing

Prenatal Testing

Monogenic Disease Testing Segment by Application

Hospitals

Clinics

Others

Monogenic Disease Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monogenic Disease Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monogenic Disease Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monogenic Disease Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Monogenic Disease Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Monogenic Disease Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monogenic Disease Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Monogenic Disease Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Carrier Testing Major Player Table 3. Diagnostic Testing Major Player Table 4. New-Born Screening Major Player Table 5. Predictive and Pre-Symptomatic Testing Major Player Table 6. Prenatal Testing Major Player Table 7. Global Monogenic Disease Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Clinics Major Player Table 10. Others Major Player Table 11. Monogenic Disease Testing Industry Trends Table 12. Monogenic Disease Testing Industry Drivers Table 13. Monogenic Disease Testing Industry Opportunities and Challenges Table 14. Monogenic Disease Testing Industry Restraints Table 15. Global Monogenic Disease Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Monogenic Disease Testing Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Monogenic Disease Testing Market Share by Region (2021-2026) Table 18. Global Monogenic Disease Testing Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Monogenic Disease Testing Market Share by Region (2027-2032) Table 20. Global Monogenic Disease Testing Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Monogenic Disease Testing Revenue Market Share by Players (2021-2026) Table 22. Global Monogenic Disease Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Monogenic Disease Testing Key Players Headquarters & Area Served Table 24. Global Monogenic Disease Testing Players, Product Type & Application Table 25. Global Monogenic Disease Testing Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Monogenic Disease Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Monogenic Disease Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Monogenic Disease Testing Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Monogenic Disease Testing Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Monogenic Disease Testing Revenue Market Share by Type (2021-2026) Table 32. Global Monogenic Disease Testing Revenue Market Share by Type (2027-2032) Table 33. Global Monogenic Disease Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Monogenic Disease Testing Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Monogenic Disease Testing Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Monogenic Disease Testing Revenue Market Share by Application (2021-2026) Table 37. Global Monogenic Disease Testing Revenue Market Share by Application (2027-2032) Table 38. Celera Support Services Company Information Table 39. Celera Support Services Business Overview Table 40. Celera Support Services Monogenic Disease Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Celera Support Services Monogenic Disease Testing Product Portfolio Table 42. Celera Support Services Recent Development Table 43. Abbott Company Information Table 44. Abbott Business Overview Table 45. Abbott Monogenic Disease Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Abbott Monogenic Disease Testing Product Portfolio Table 47. Abbott Recent Development Table 48. ELITech Group Company Information Table 49. ELITech Group Business Overview Table 50. ELITech Group Monogenic Disease Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. ELITech Group Monogenic Disease Testing Product Portfolio Table 52. ELITech Group Recent Development Table 53. Auto Genomics Company Information Table 54. Auto Genomics Business Overview Table 55. Auto Genomics Monogenic Disease Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Auto Genomics Monogenic Disease Testing Product Portfolio Table 57. Auto Genomics Recent Development Table 58. PerkinElmer Company Information Table 59. PerkinElmer Business Overview Table 60. PerkinElmer Monogenic Disease Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. PerkinElmer Monogenic Disease Testing Product Portfolio Table 62. PerkinElmer Recent Development Table 63. Bio-Rad Laboratories Company Information Table 64. Bio-Rad Laboratories Business Overview Table 65. Bio-Rad Laboratories Monogenic Disease Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Bio-Rad Laboratories Monogenic Disease Testing Product Portfolio Table 67. Bio-Rad Laboratories Recent Development Table 68. North America Monogenic Disease Testing Revenue by Type (2021-2026) & (US$ Million) Table 69. North America Monogenic Disease Testing Revenue by Type (2027-2032) & (US$ Million) Table 70. North America Monogenic Disease Testing Revenue by Application (2021-2026) & (US$ Million) Table 71. North America Monogenic Disease Testing Revenue by Application (2027-2032) & (US$ Million) Table 72. North America Monogenic Disease Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. North America Monogenic Disease Testing Revenue by Country (2021-2026) & (US$ Million) Table 74. North America Monogenic Disease Testing Revenue by Country (US$ Million) & (2027-2032) Table 75. Europe Monogenic Disease Testing Revenue by Type (2021-2026) & (US$ Million) Table 76. Europe Monogenic Disease Testing Revenue by Type (2027-2032) & (US$ Million) Table 77. Europe Monogenic Disease Testing Revenue by Application (2021-2026) & (US$ Million) Table 78. Europe Monogenic Disease Testing Revenue by Application (2027-2032) & (US$ Million) Table 79. Europe Monogenic Disease Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. Europe Monogenic Disease Testing Revenue by Country (2021-2026) & (US$ Million) Table 81. Europe Monogenic Disease Testing Revenue by Country (US$ Million) & (2027-2032) Table 82. China Monogenic Disease Testing Revenue by Type (2021-2026) & (US$ Million) Table 83. China Monogenic Disease Testing Revenue by Type (2027-2032) & (US$ Million) Table 84. China Monogenic Disease Testing Revenue by Application (2021-2026) & (US$ Million) Table 85. China Monogenic Disease Testing Revenue by Application (2027-2032) & (US$ Million) Table 86. Asia Monogenic Disease Testing Revenue by Type (2021-2026) & (US$ Million) Table 87. Asia Monogenic Disease Testing Revenue by Type (2027-2032) & (US$ Million) Table 88. Asia Monogenic Disease Testing Revenue by Application (2021-2026) & (US$ Million) Table 89. Asia Monogenic Disease Testing Revenue by Application (2027-2032) & (US$ Million) Table 90. Asia Monogenic Disease Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 91. Asia Monogenic Disease Testing Revenue by Region (US$ Million) & (2021-2026) Table 92. Asia Monogenic Disease Testing Revenue by Region (US$ Million) & (2027-2032) Table 93. SAMEA Monogenic Disease Testing Revenue by Type (2021-2026) & (US$ Million) Table 94. SAMEA Monogenic Disease Testing Revenue by Type (2027-2032) & (US$ Million) Table 95. SAMEA Monogenic Disease Testing Revenue by Application (2021-2026) & (US$ Million) Table 96. SAMEA Monogenic Disease Testing Revenue by Application (2027-2032) & (US$ Million) Table 97. SAMEA Monogenic Disease Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. SAMEA Monogenic Disease Testing Revenue by Country (2021-2026) & (US$ Million) Table 99. SAMEA Monogenic Disease Testing Revenue by Country (US$ Million) & (2027-2032) Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Monogenic Disease Testing Image Figure 2. Global Monogenic Disease Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monogenic Disease Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Carrier Testing Image Figure 5. Diagnostic Testing Image Figure 6. New-Born Screening Image Figure 7. Predictive and Pre-Symptomatic Testing Image Figure 8. Prenatal Testing Image Figure 9. Global Monogenic Disease Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Monogenic Disease Testing Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Others Image Figure 14. Global Monogenic Disease Testing Market Size (US$ Million) & (2021-2032) Figure 15. Global Monogenic Disease Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Monogenic Disease Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Monogenic Disease Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Monogenic Disease Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Monogenic Disease Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Monogenic Disease Testing Revenue Market Share by Type (2021-2032) Figure 22. Global Monogenic Disease Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Monogenic Disease Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Monogenic Disease Testing Revenue Market Share by Application (2021-2032) Figure 25. North America Monogenic Disease Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Monogenic Disease Testing Revenue Share by Type (2021-2032) Figure 27. North America Monogenic Disease Testing Revenue Share by Application (2021-2032) Figure 28. North America Monogenic Disease Testing Revenue Share by Country (2021-2032) Figure 29. United States Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Monogenic Disease Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Monogenic Disease Testing Revenue Share by Type (2021-2032) Figure 34. Europe Monogenic Disease Testing Revenue Share by Application (2021-2032) Figure 35. Europe Monogenic Disease Testing Revenue Share by Country (2021-2032) Figure 36. Germany Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Monogenic Disease Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Monogenic Disease Testing Revenue Share by Type (2021-2032) Figure 46. China Monogenic Disease Testing Revenue Share by Application (2021-2032) Figure 47. Asia Monogenic Disease Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Monogenic Disease Testing Revenue Share by Type (2021-2032) Figure 49. Asia Monogenic Disease Testing Revenue Share by Application (2021-2032) Figure 50. Asia Monogenic Disease Testing Revenue Share by Region (2021-2032) Figure 51. Japan Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Monogenic Disease Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Monogenic Disease Testing Revenue Share by Type (2021-2032) Figure 59. SAMEA Monogenic Disease Testing Revenue Share by Application (2021-2032) Figure 60. SAMEA Monogenic Disease Testing Revenue Share by Country (2021-2032) Figure 61. Brazil Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Monogenic Disease Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Carrier Testing
  • Diagnostic Testing
  • New-Born Screening
  • Predictive and Pre-Symptomatic Testing
  • Prenatal Testing
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Celera Support Services
  • Abbott
  • ELITech Group
  • Auto Genomics
  • PerkinElmer
  • Bio-Rad Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Monogenic Disease Testing Market by Type
  3. 1.2.1 Global Monogenic Disease Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Carrier Testing
  5. 1.2.3 Diagnostic Testing
  6. 1.2.4 New-Born Screening
  7. 1.2.5 Predictive and Pre-Symptomatic Testing
  8. 1.2.6 Prenatal Testing
  9. 1.3 Monogenic Disease Testing Market by Application
  10. 1.3.1 Global Monogenic Disease Testing Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Clinics
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Monogenic Disease Testing Market Dynamics
  1. 2.1 Monogenic Disease Testing Industry Trends
  2. 2.2 Monogenic Disease Testing Industry Drivers
  3. 2.3 Monogenic Disease Testing Industry Opportunities and Challenges
  4. 2.4 Monogenic Disease Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Monogenic Disease Testing Market Perspective (2021-2032)
  2. 3.2 Global Monogenic Disease Testing Growth Trends by Region
  3. 3.2.1 Global Monogenic Disease Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Monogenic Disease Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Monogenic Disease Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Monogenic Disease Testing Revenue by Players
  2. 4.1.1 Global Monogenic Disease Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Monogenic Disease Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Monogenic Disease Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Monogenic Disease Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Monogenic Disease Testing Key Players Headquarters & Area Served
  7. 4.4 Global Monogenic Disease Testing Players, Product Type & Application
  8. 4.5 Global Monogenic Disease Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Monogenic Disease Testing Market CR5 and HHI
  11. 4.6.3 2025 Monogenic Disease Testing Tier 1, Tier 2, and Tier 3
5 Monogenic Disease Testing Market Size by Type
  1. 5.1 Global Monogenic Disease Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Monogenic Disease Testing Revenue by Type (2021-2032)
  3. 5.3 Global Monogenic Disease Testing Revenue Market Share by Type (2021-2032)
6 Monogenic Disease Testing Market Size by Application
  1. 6.1 Global Monogenic Disease Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Monogenic Disease Testing Revenue by Application (2021-2032)
  3. 6.3 Global Monogenic Disease Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Celera Support Services
  2. 7.1.1 Celera Support Services Company Information
  3. 7.1.2 Celera Support Services Business Overview
  4. 7.1.3 Celera Support Services Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Celera Support Services Monogenic Disease Testing Product Portfolio
  6. 7.1.5 Celera Support Services Recent Developments
  7. 7.2 Abbott
  8. 7.2.1 Abbott Company Information
  9. 7.2.2 Abbott Business Overview
  10. 7.2.3 Abbott Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Abbott Monogenic Disease Testing Product Portfolio
  12. 7.2.5 Abbott Recent Developments
  13. 7.3 ELITech Group
  14. 7.3.1 ELITech Group Company Information
  15. 7.3.2 ELITech Group Business Overview
  16. 7.3.3 ELITech Group Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ELITech Group Monogenic Disease Testing Product Portfolio
  18. 7.3.5 ELITech Group Recent Developments
  19. 7.4 Auto Genomics
  20. 7.4.1 Auto Genomics Company Information
  21. 7.4.2 Auto Genomics Business Overview
  22. 7.4.3 Auto Genomics Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Auto Genomics Monogenic Disease Testing Product Portfolio
  24. 7.4.5 Auto Genomics Recent Developments
  25. 7.5 PerkinElmer
  26. 7.5.1 PerkinElmer Company Information
  27. 7.5.2 PerkinElmer Business Overview
  28. 7.5.3 PerkinElmer Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 PerkinElmer Monogenic Disease Testing Product Portfolio
  30. 7.5.5 PerkinElmer Recent Developments
  31. 7.6 Bio-Rad Laboratories
  32. 7.6.1 Bio-Rad Laboratories Company Information
  33. 7.6.2 Bio-Rad Laboratories Business Overview
  34. 7.6.3 Bio-Rad Laboratories Monogenic Disease Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bio-Rad Laboratories Monogenic Disease Testing Product Portfolio
  36. 7.6.5 Bio-Rad Laboratories Recent Developments
8 North America
  1. 8.1 North America Monogenic Disease Testing Revenue (2021-2032)
  2. 8.2 North America Monogenic Disease Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Monogenic Disease Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Monogenic Disease Testing Revenue by Type (2027-2032)
  5. 8.3 North America Monogenic Disease Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Monogenic Disease Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Monogenic Disease Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Monogenic Disease Testing Revenue by Application (2027-2032)
  9. 8.5 North America Monogenic Disease Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Monogenic Disease Testing Revenue by Country
  11. 8.6.1 North America Monogenic Disease Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Monogenic Disease Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Monogenic Disease Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Monogenic Disease Testing Revenue (2021-2032)
  2. 9.2 Europe Monogenic Disease Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Monogenic Disease Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Monogenic Disease Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Monogenic Disease Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Monogenic Disease Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Monogenic Disease Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Monogenic Disease Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Monogenic Disease Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Monogenic Disease Testing Revenue by Country
  11. 9.6.1 Europe Monogenic Disease Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Monogenic Disease Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Monogenic Disease Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Monogenic Disease Testing Revenue (2021-2032)
  2. 10.2 China Monogenic Disease Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Monogenic Disease Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Monogenic Disease Testing Revenue by Type (2027-2032)
  5. 10.3 China Monogenic Disease Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Monogenic Disease Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Monogenic Disease Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Monogenic Disease Testing Revenue by Application (2027-2032)
  9. 10.5 China Monogenic Disease Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Monogenic Disease Testing Revenue (2021-2032)
  2. 11.2 Asia Monogenic Disease Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Monogenic Disease Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Monogenic Disease Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Monogenic Disease Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Monogenic Disease Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Monogenic Disease Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Monogenic Disease Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Monogenic Disease Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Monogenic Disease Testing Revenue by Country
  11. 11.6.1 Asia Monogenic Disease Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Monogenic Disease Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Monogenic Disease Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Monogenic Disease Testing Revenue (2021-2032)
  2. 12.2 SAMEA Monogenic Disease Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Monogenic Disease Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Monogenic Disease Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Monogenic Disease Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Monogenic Disease Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Monogenic Disease Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Monogenic Disease Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Monogenic Disease Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Monogenic Disease Testing Revenue by Country
  11. 12.6.1 SAMEA Monogenic Disease Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Monogenic Disease Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Monogenic Disease Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst